India's health ministry said the government plans to spend $27.3 million to establish ten clusters around the country for drug makers to share common production facilities and reduce their costs by 25%.
India physicians report an uptick in the number of tuberculosis cases occurring not in the lungs, but elsewhere in the body even as they criticize the government for failing to see that patients have access to the drugs they need to treat the disease.
Having faced years of criticism for its failure to publish guidelines on how the industry can use social media, the FDA is now being chastised by the advocacy group Union of Concerned Scientists over its lack of a policy for its staff.
The FDA is rushing to complete guidance on abuse-deterrent opioids before the end of June because if it doesn't, Congress has promised to take away $20 million in money for salaries and expenses in the FDA Commissioner's Office and give it instead to its criminal investigations unit to fight drug diversion.
India's National Pharmaceutical Pricing Authority has ordered all drugmakers to pass along to the consumer the recent reduction in the excise duty on imported medicines.
Foreign drugmakers could be about to get at least some of the increased patent protection they have been pressing for in India, if a government proposal in a related industry is any indication.
Good news for GlaxoSmithKline: An FDA panel of experts says the efficacy and safety data for blockbuster wannabe Breo support the asthma indication it's gunning for in adults 18 and older. When it comes to children aged 12 to 17, though? The panelists aren't having it.
The U.S. FDA is adopting a "carrot and stick" approach to the problems with India's pharmaceutical production. The new plan calls for rating India drugmakers and providing incentives for meeting good manufacturing practices along with use of its usual enforcement tools.
After staving off Treasury Department rules, angry politicians and antitrust regulators, Medtronic is earning early victories from its $50 billion mega-acquisition of Covidien. The company announced that the former rival's Protégé GPS peripheral stent for treating peripheral artery disease now has the FDA's blessing to be used against lesions in the common and external iliac arteries, located in the pelvis.
The FDA is putting robot assisted surgery in the spotlight this summer.